2seventy bio Presents Data Across Multiple Cell Therapy Prog

14.12.2021 - 2seventy bio, Inc. (NASDAQ: TSVT) today announced data from its broad oncology cell therapy portfolio, including updated results from the CRB-402 study of bb21217 and new analyses from the pivotal KarMMa study of ABECMA (idecabtagene vicleucel; ...

Related Keywords

Switzerland , Canada , Hemophagocytic Lymphohistiocytosis , Linkedin , Twitter , European Union , Bristol Myers Squibb , Key Insights , New Data , Multiple Myeloma Continue , Release Syndrome , Innovative Approach , Acute Myeloid Leukemia , Dimerizing Agent Regulated Immunoreceptor Complex , Seattle Children , Profit Share Agreement , Bristol Myers , Macrophage Activation Syndrome , Risk Evaluation , Mitigation Strategy , Igg Secondary Malignancies , Operate Machinery , Prescribing Information , Cautionary Statement Regarding Forward Looking , 2seventy Bio ,